VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) | VYVGART (efgartigimod alfa-fcab) VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) | VYVGART (efgartigimod alfa-fcab)
Prescription medicines for adults with anti-AChR antibody positive generalized myasthenia gravis (gMG)
MENU

Questions? Call 1-833-VYVGART (1-833-898-4278)

Prescription medicines for adults with anti-AChR antibody positive generalized myasthenia gravis (gMG)
STAY UP TO DATE

Questions? Call 1-833-VYVGART (1-833-898-4278)

Finding the right VYVGART dosing cycle for me

Doug was diagnosed with anti-AChR antibody positive gMG in 2017 and started on VYVGART for intravenous (IV) infusion in 2022. In this guest post, he talks about his personalized VYVGART dosing schedule—and how symptom tracking helps determine his breaks between treatment cycles.

Doug
Started on VYVGART for IV infusion in 2022

Doug is a paid spokesperson of argenx.

I grew up on a family farm, and that’s where my strong work ethic came from. I was used to having chores to do at dawn before school every day, and I carried that with me into my dual careers in nursing and the Army Reserves. I chose this path because of my lifelong determination to work hard, be responsible for myself and for others, and keep up an active lifestyle.

This began to change in 2017 when I started having difficulty chewing and trouble with my vision. These symptoms are what led to my diagnosis of gMG a few months later. I began seeing a neurologist, and I tried a few treatments before landing on VYVGART for IV infusion. Before I got started, my doctor let me know that the most common side effects are respiratory tract infection, headache, and urinary tract infection. Part of getting started with VYVGART was understanding how dosing works and working with my doctor to figure out how long my personalized break would be before my next cycle.

Doug Doug Doug

For readers who may not know, here’s how dosing works for VYVGART for IV infusion: For each treatment cycle, you’ll receive 4 treatments—1 treatment each week for 4 weeks in a row. After that, you take a break of at least 4 weeks before starting your next treatment cycle. You and your doctor work together to keep track of your symptoms. When they start to return, it’s time to talk to your doctor about starting your next cycle.*

“Symptom tracking helps your doctor determine when to start your next treatment cycle.”

I like that the break between VYVGART treatment cycles can be personalized to me. Right now, I’m on a quarterly schedule, which means that after each 4-week treatment cycle, I have a break of about 8 weeks, which my doctor may adjust based on my symptoms and side effects. But, of course, everyone’s symptoms are different, and different people may need different lengths of time between treatment cycles. Sometimes, a break may be a set amount of time like mine, and sometimes it may vary instead.

One of the things that’s really helped me is tracking my symptoms with the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale. If you haven’t heard of it, it’s a scale where you rate your gMG symptoms based on how you’re feeling. There are 8 common signs and symptoms on the scale, and you put a score to each. If you’re not experiencing a particular symptom at all, it’s a 0. When a symptom is at its most severe, it’s a 3.

Doug Doug Doug
Doug Doug Doug

I track my own MG-ADL score once a week. By looking at my scores, I get a better sense of how I’m doing with my gMG management and personalized breaks between treatment cycles. I also think it’s important to share this information with my doctor. That’s because symptom tracking helps your doctor determine when to start your next treatment cycle.

Right now, my treatment cycles are on a consistent schedule. But if my symptoms were to start flaring up during my break between treatment cycles, my MG-ADL score would also help me spot that. I’d be able to see my scores starting to go up and use those scores to talk to my doctor about planning my next treatment cycle—and maybe even adjusting my breaks between treatment cycles as needed in the future.

Want to find your own MG-ADL symptom score?

USE THE INTERACTIVE TOOL

Overall, I feel good about how my VYVGART cycles have been working. My treatment cycle is flexible enough that I can always schedule my infusion appointments for Wednesdays. That’s my “me” day, and I like knowing that I can plan my treatments around the other things happening in my life.

With VYVGART, I have been able to manage my gMG symptoms well. As I get older, my hope is to keep doing some of the things that I love. And with personalized breaks between treatment cycles, I know I’ll have options if my symptoms ever start showing up more frequently between cycles.

*Your neurologist will work with you to help determine when you need another treatment cycle, if additional cycles are needed, with the aim to help manage your symptoms. The safety of starting the next treatment cycle sooner than 4 weeks from the last infusion of the previous treatment cycle has not been established.
AChR=acetylcholine receptor.

VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) | VYVGART (efgartigimod alfa-fcab)
VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) | VYVGART (efgartigimod alfa-fcab)

Still have questions? Call 1-833-VYVGART (1-833-898-4278) to speak with an educator about gMG, how VYVGART works in the body, study data, cost and coverage, and more.

Do not take VYVGART if you are allergic to efgartigimod alfa or any of the ingredients in VYVGART. Do not take VYVGART HYTRULO if you are allergic to efgartigimod alfa, hyaluronidase, or any of the ingredients in VYVGART HYTRULO. VYVGART or VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.

Before taking VYVGART or VYVGART HYTRULO, tell your healthcare provider about all of your medical conditions, including if you:

  • have an infection or fever.
  • have recently received or are scheduled to receive any vaccinations.
  • have any history of allergic reactions.
  • have kidney (renal) problems.
  • are pregnant or plan to become pregnant. It is not known whether VYVGART or VYVGART HYTRULO will harm your unborn baby.
    • Pregnancy Exposure Registry. There is a pregnancy exposure registry for women who use VYVGART or VYVGART HYTRULO during pregnancy. The purpose of this registry is to collect information about your health and your baby. Your healthcare provider can enroll you in this registry. You may also enroll yourself or get more information about the registry by calling 1-855-272-6524 or going to VYVGARTPregnancy.com
  • are breastfeeding or plan to breastfeed. It is not known if VYVGART or VYVGART HYTRULO passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

VYVGART or VYVGART HYTRULO can cause side effects which can be serious, including:

  • Infection. VYVGART or VYVGART HYTRULO may increase the risk of infection. If you have an active infection, your healthcare provider should delay your treatment with VYVGART or VYVGART HYTRULO until your infection is gone. Tell your healthcare provider right away if you get any of the following signs and symptoms of an infection:
    • fever
    • chills
    • frequent and painful urination
    • cough
    • pain and blockage of nasal passages
    • wheezing
    • shortness of breath
    • sore throat
    • excess phlegm
    • nasal discharge
  • Allergic reactions (hypersensitivity reactions). VYVGART or VYVGART HYTRULO can cause allergic reactions that can be severe. These reactions can happen during, shortly after, or weeks after your VYVGART infusion or VYVGART HYTRULO injection. Tell your healthcare provider or get emergency help right away if you have any of the following symptoms of an allergic reaction with VYVGART or VYVGART HYTRULO:
    • rash
    • swelling of the face, lips, throat, or tongue
    • shortness of breath
    • trouble breathing
    • low blood pressure
    • fainting

An additional symptom of an allergic reaction with VYVGART HYTRULO can include hives.

  • Infusion or injection-related reactions. VYVGART can cause infusion-related reactions. VYVGART HYTRULO can cause infusion or injection-related reactions. These reactions can happen during or shortly after your VYVGART infusion or VYVGART HYTRULO injection. Tell your healthcare provider if you have any of the following symptoms of an infusion or injection-related reaction:
    • high blood pressure
    • chills
    • shivering
    • chest, stomach, or back pain

The most common side effects of VYVGART or VYVGART HYTRULO include respiratory tract infection, headache, and urinary tract infection. An additional common side effect with VYVGART HYTRULO includes injection site reactions.

These are not all the possible side effects of VYVGART or VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is VYVGART® (efgartigimod alfa-fcab) for intravenous (IV) infusion and what is VYVGART HYTRULO® (efgartigimod alfa and hyaluronidase-qvfc) for subcutaneous injection?

VYVGART and VYVGART HYTRULO are both prescription medicines used to treat adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.

It is not known if VYVGART or VYVGART HYTRULO is safe and effective in children.

Please see full Prescribing and Patient Information for VYVGART HYTRULO for subcutaneous injection and full Prescribing Information for VYVGART for IV infusion.

Dosage forms and strengths:

VYVGART Hytrulo is available as a single-dose subcutaneous injection containing: 200 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per prefilled syringe, or 180 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per vial. VYVGART is available as a single-dose injection for intravenous use containing 400 mg/20 mL of efgartigimod alfa-fcab per vial.

Do not take VYVGART if you are allergic to efgartigimod alfa or any of the ingredients in VYVGART. Do not take VYVGART HYTRULO if you are allergic to efgartigimod alfa, hyaluronidase, or any of the ingredients in VYVGART HYTRULO. VYVGART or VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.

Before taking VYVGART or VYVGART HYTRULO, tell your healthcare provider about all of your medical conditions, including if you:

  • have an infection or fever.
  • have recently received or are scheduled to receive any vaccinations.
  • have any history of allergic reactions.
  • have kidney (renal) problems.
  • are pregnant or plan to become pregnant. It is not known whether VYVGART or VYVGART HYTRULO will harm your unborn baby.
    • Pregnancy Exposure Registry. There is a pregnancy exposure registry for women who use VYVGART or VYVGART HYTRULO during pregnancy. The purpose of this registry is to collect information about your health and your baby. Your healthcare provider can enroll you in this registry. You may also enroll yourself or get more information about the registry by calling 1-855-272-6524 or going to VYVGARTPregnancy.com
  • are breastfeeding or plan to breastfeed. It is not known if VYVGART or VYVGART HYTRULO passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

VYVGART or VYVGART HYTRULO can cause side effects which can be serious, including:

  • Infection. VYVGART or VYVGART HYTRULO may increase the risk of infection. If you have an active infection, your healthcare provider should delay your treatment with VYVGART or VYVGART HYTRULO until your infection is gone. Tell your healthcare provider right away if you get any of the following signs and symptoms of an infection:
    • fever
    • chills
    • frequent and painful urination
    • cough
    • pain and blockage of nasal passages
    • wheezing
    • shortness of breath
    • sore throat
    • excess phlegm
    • nasal discharge
  • Allergic reactions (hypersensitivity reactions). VYVGART or VYVGART HYTRULO can cause allergic reactions that can be severe. These reactions can happen during, shortly after, or weeks after your VYVGART infusion or VYVGART HYTRULO injection. Tell your healthcare provider or get emergency help right away if you have any of the following symptoms of an allergic reaction with VYVGART or VYVGART HYTRULO:
    • rash
    • swelling of the face, lips, throat, or tongue
    • shortness of breath
    • trouble breathing
    • low blood pressure
    • fainting

An additional symptom of an allergic reaction with VYVGART HYTRULO can include hives.

  • Infusion or injection-related reactions. VYVGART can cause infusion-related reactions. VYVGART HYTRULO can cause infusion or injection-related reactions. These reactions can happen during or shortly after your VYVGART infusion or VYVGART HYTRULO injection. Tell your healthcare provider if you have any of the following symptoms of an infusion or injection-related reaction:
    • high blood pressure
    • chills
    • shivering
    • chest, stomach, or back pain

The most common side effects of VYVGART or VYVGART HYTRULO include respiratory tract infection, headache, and urinary tract infection. An additional common side effect with VYVGART HYTRULO includes injection site reactions.

These are not all the possible side effects of VYVGART or VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is VYVGART® (efgartigimod alfa-fcab) for intravenous (IV) infusion and what is VYVGART HYTRULO® (efgartigimod alfa and hyaluronidase-qvfc) for subcutaneous injection?

VYVGART and VYVGART HYTRULO are both prescription medicines used to treat adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.

It is not known if VYVGART or VYVGART HYTRULO is safe and effective in children.

Please see full Prescribing and Patient Information for VYVGART HYTRULO for subcutaneous injection and full Prescribing Information for VYVGART for IV infusion.

Dosage forms and strengths:

VYVGART Hytrulo is available as a single-dose subcutaneous injection containing: 200 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per prefilled syringe, or 180 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per vial. VYVGART is available as a single-dose injection for intravenous use containing 400 mg/20 mL of efgartigimod alfa-fcab per vial.

Questions? Call 1-833-VYVGART
(1-833-898-4278)

This site is intended for patients and caregivers.

Disclaimer | Privacy Policy | Contact Us |

Patient and Prescribing Information
VYVGART Hytrulo Patient Information VYVGART Hytrulo Prescribing Information VYVGART Hytrulo Prefilled Syringe Instructions for Use VYVGART for IV Infusion Prescribing Information

VYVGART and VYVGART Hytrulo are registered trademarks of argenx.

For U.S. audiences only.

©2025 argenx 

US-VYV-23-00229 V11 06/2025

argenx